HVTN 111

A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,

Enrollment Opened

Objectives

-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

-To evaluate  immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

Trial design

Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.

Funder/Sponsor

NIH/DAIDS HVTN

 

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send as an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya Did you know @NIMRMbeya has conducted 7 early stage HIV vaccine studies? We're part of a global effort with… https://t.co/EwTZZwBY18
NIMRMbeya You can Read more about the SMERT project at: https://t.co/kgNS8UR8uW #NIMR @EDCTP @mgaya_prof @NNtinginya @univofstandrews
NIMRMbeya NIMR through its Mbeya branch in collaboration with the University of St Andrews, TFDA, NatHREC and KCRI launch the… https://t.co/JmjNkE6Tj6
NIMRMbeya 2018 World TB Day Commemorations at Uyole, Mbeya. #WorldTBDay #EndTB @TBAlliance @HVTN @TBSequel @PanACEA_IIhttps://t.co/WGHZ8PXrtT
© 2017 NIMR - Mbeya Medical Research Center